160 related articles for article (PubMed ID: 577180)
21. [Hormonal contraception--side effects and surgical aspects (author's transl)].
Göretzlehner G; Carol W; Köhler G
Zentralbl Chir; 1980; 105(24):1601-16. PubMed ID: 7015744
[TBL] [Abstract][Full Text] [Related]
22. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
Schneider WH; Schmid R; Spona J
Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
[TBL] [Abstract][Full Text] [Related]
23. Sensitive detection of the endocrine effects of the estrogen analogue ethinylestradiol using a modified enhanced subacute rat study protocol (OECD Test Guideline no. 407).
Andrews P; Freyberger A; Hartmann E; Eiben R; Loof I; Schmidt U; Temerowski M; Folkerts A; Stahl B; Kayser M
Arch Toxicol; 2002 May; 76(4):194-202. PubMed ID: 12029382
[TBL] [Abstract][Full Text] [Related]
24. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
Henzl MR; Loomba PK
J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
[TBL] [Abstract][Full Text] [Related]
25. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
Gaspard U; Dubois M
Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
[TBL] [Abstract][Full Text] [Related]
26. [Chemical aspects of steroidal contraceptives].
Benoit-guyod J-l
Chim Ther; 1967; 2(5):383-94. PubMed ID: 12334343
[TBL] [Abstract][Full Text] [Related]
27. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
28. [Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations].
Oettel M; Carol W; Gräser T; Klinger G; Mellinger U; Moore C; Schindler AE; Winkler UH
Zentralbl Gynakol; 1997; 119(12):597-606. PubMed ID: 9483810
[TBL] [Abstract][Full Text] [Related]
29. [Current developments in hormonal contraception].
Kuhl H
Gynakologe; 1992 Aug; 25(4):231-40. PubMed ID: 1398252
[TBL] [Abstract][Full Text] [Related]
30. Anabolic and androgenic activity of 19-norandrostenedione after oral and subcutaneous administration--analysis of side effects and metabolism.
Parr MK; Laudenbach-Leschowsky U; Höfer N; Schänzer W; Diel P
Toxicol Lett; 2009 Jul; 188(2):137-41. PubMed ID: 19446246
[TBL] [Abstract][Full Text] [Related]
31. [Combined estrogen-progestagen contraception and glucid and water-sodium metabolism].
Belaisch J; Hommais-loufrani B
Contracept Fertil Sex (Paris); 1988 Feb; 16(2):3-7. PubMed ID: 12342001
[TBL] [Abstract][Full Text] [Related]
32. Oral contraception.
Helles AA
Arch Pharm Chem (Kbh); 1971; 78():2-9. PubMed ID: 12334380
[TBL] [Abstract][Full Text] [Related]
33. Progestagenic and antigonadotrophic activities of STS 557.
Stölzner W; Kurischko A; Freund H; Freund R; Meyer M; Oettel M
Exp Clin Endocrinol; 1983 Feb; 81(2):115-21. PubMed ID: 6189734
[TBL] [Abstract][Full Text] [Related]
34. [Hypophyseal reaction state during oral contraceptiva (author's transl)].
Gitsch E; Schneider WH; Schmid R; Spona J
Wien Klin Wochenschr; 1981 Oct; 93(19):599-601. PubMed ID: 6798764
[TBL] [Abstract][Full Text] [Related]
35. Relationship between uterotrophic and interceptive activities of steroidal estrogens.
Oettel M; Draffehn J; Koch M; Kurischko A; Ohme E; Strecke J; Tiroke I
Endokrinologie; 1978 Apr; 72(1):25-35. PubMed ID: 567577
[TBL] [Abstract][Full Text] [Related]
36. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
37. [Residual function in the ovary during low-dose oral contraceptive treatment].
Pearson S; Skouby SO
Ugeskr Laeger; 1989 Jun; 151(23):1465-8. PubMed ID: 2734951
[TBL] [Abstract][Full Text] [Related]
38. The androgenicity of progestational agents.
Lobo RA
Int J Fertil; 1988; 33 Suppl():6-12. PubMed ID: 2908040
[TBL] [Abstract][Full Text] [Related]
39. [Inhibition of ovulation by means of estrogen depot and gestagen depot].
Hashiguchi A
Sanfujinka No Jissai; 1969 Apr; 18(4):334-9. PubMed ID: 5819860
[No Abstract] [Full Text] [Related]
40. Effects of hydroxyflutamide on female reproductive function.
Chandrasekhar Y
Adv Contracept Deliv Syst; 1991; 7(2):157-66. PubMed ID: 12284218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
